Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.

Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, Lang PC, Petrone M, Rafii S.

Exp Hematol. 2001 Dec;29(12):1417-24.

PMID:
11750100
2.

[Anagrelide--new antiplatelet drug].

Robak T, Treliński J, Hołub A.

Acta Haematol Pol. 1994;25(4):309-15. Review. Polish.

PMID:
7847031
3.

Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.

Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr.

Semin Thromb Hemost. 1997;23(4):379-83. Review.

PMID:
9263355
5.

Physiologic role of TPO in thrombopoiesis.

Miyazaki H.

Stem Cells. 1996;14 Suppl 1:133-8. Review.

6.

Anagrelide, a selective thrombocytopenic agent.

Oertel MD.

Am J Health Syst Pharm. 1998 Oct 1;55(19):1979-86. Review.

PMID:
9784784
7.

Anagrelide: a review of its use in the management of essential thrombocythaemia.

Wagstaff AJ, Keating GM.

Drugs. 2006;66(1):111-31. Review.

PMID:
16398570
8.

Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations.

McCune JS, Liles D, Lindley C.

Pharmacotherapy. 1997 Jul-Aug;17(4):822-6. Review.

PMID:
9250565
9.

Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.

Hong Y, Erusalimsky JD.

Platelets. 2002 Nov;13(7):381-6. Review. No abstract available.

PMID:
12487784

Supplemental Content

Support Center